000			01752 a2200421 4500
005			20250515182353.0
264		0	_c20091224
008			200912s 0 0 eng d
022			_a1523-1755
024	7		_a10.1038/ki.2009.296 _2doi
040			_aNLM _beng _cNLM
100	1		_aClark, Peter E
245	0	0	_aThe role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. _h[electronic resource]
260			_bKidney international _cNov 2009
300			_a939-45 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Review
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAryl Hydrocarbon Receptor Nuclear Translocator _xgenetics
650	0	4	_aCarcinoma, Renal Cell _xdrug therapy
650	0	4	_aDrug Design
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aHumans
650	0	4	_aHypoxia-Inducible Factor 1, alpha Subunit _xgenetics
650	0	4	_aKidney Neoplasms _xgenetics
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aProtein Kinases _xdrug effects
650	0	4	_aReceptors, Vascular Endothelial Growth Factor _xantagonists & inhibitors
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aTOR Serine-Threonine Kinases
650	0	4	_aTranslational Research, Biomedical
650	0	4	_aTreatment Outcome
650	0	4	_aVascular Endothelial Growth Factor A _xantagonists & inhibitors
650	0	4	_aVon Hippel-Lindau Tumor Suppressor Protein _xgenetics
773	0		_tKidney international _gvol. 76 _gno. 9 _gp. 939-45
856	4	0	_uhttps://doi.org/10.1038/ki.2009.296 _zAvailable from publisher's website
999			_c19064194 _d19064194